{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T10:16:17Z","timestamp":1792145777258,"version":"4.4.0"},"reference-count":86,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T00:00:00Z","timestamp":1681948800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,7,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Although evidence indicates the association of lipoprotein(a) [Lp(a)] with atherosclerosis, the link with calcific aortic valve disease (CAVD) is unclear. This systematic review and meta-analysis explores the connection between Lp(a) and aortic valve calcification and stenosis (AVS). We included all relevant studies, indexed in eight databases, up to February 2023. A total of 44 studies (163 139 subjects) were included, with 16 of them being further meta-analysed. Despite considerable heterogeneity, most studies support the relationship between Lp(a) and CAVD, especially in younger populations, with evidence of early aortic valve micro-calcification in elevated-Lp(a) populations. The quantitative synthesis showed higher Lp(a) levels, by 22.63 nmol\/L (95% CI: 9.98\u201335.27), for patients with AVS, while meta-regressing the data revealed smaller Lp(a) differences for older populations with a higher proportion of females. The meta-analysis of eight studies providing genetic data, revealed that the minor alleles of both rs10455872 and rs3798220 LPA gene loci were associated with higher risk for AVS (pooled odds ratio 1.42; 95% CI: 1.34\u20131.50 and 1.27; 95% CI: 1.09\u20131.48, respectively). Importantly, high-Lp(a) individuals displayed not only faster AVS progression, by a mean difference of 0.09 m\/s\/year (95% CI: 0.09\u20130.09), but also a higher risk of serious adverse outcomes, including death (pooled hazard ratio 1.39; 95% CI: 1.01\u20131.90). These summary findings highlight the effect of Lp(a) on CAVD initiation, progression and outcomes, and support the early onset of Lp(a)-related subclinical lesions before clinical evidence.<\/jats:p>","DOI":"10.1093\/cvr\/cvad062","type":"journal-article","created":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T12:53:06Z","timestamp":1681995186000},"page":"1641-1655","source":"Crossref","is-referenced-by-count":56,"title":["Lipoprotein(a) and calcific aortic valve disease initiation and progression: a systematic review and meta-analysis"],"prefix":"10.1093","volume":"119","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5394-832X","authenticated-orcid":false,"given":"Panteleimon","family":"Pantelidis","sequence":"first","affiliation":[{"name":"3rd Department of Cardiology, National and Kapodistrian University of Athens, Medical School, Sotiria Chest Disease Hospital , 152 Mesogeion St, Athens 11527 , Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8079-0599","authenticated-orcid":false,"given":"Evangelos","family":"Oikonomou","sequence":"additional","affiliation":[{"name":"3rd Department of Cardiology, National and Kapodistrian University of Athens, Medical School, Sotiria Chest Disease Hospital , 152 Mesogeion St, Athens 11527 , Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6481-0000","authenticated-orcid":false,"given":"Stamatios","family":"Lampsas","sequence":"additional","affiliation":[{"name":"3rd Department of Cardiology, National and Kapodistrian University of Athens, Medical School, Sotiria Chest Disease Hospital , 152 Mesogeion St, Athens 11527 , Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios E","family":"Zakynthinos","sequence":"additional","affiliation":[{"name":"3rd Department of Cardiology, National and Kapodistrian University of Athens, Medical School, Sotiria Chest Disease Hospital , 152 Mesogeion St, Athens 11527 , Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonios","family":"Lysandrou","sequence":"additional","affiliation":[{"name":"3rd Department of Cardiology, National and Kapodistrian University of Athens, Medical School, Sotiria Chest Disease Hospital , 152 Mesogeion St, Athens 11527 , Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Kalogeras","sequence":"additional","affiliation":[{"name":"3rd Department of Cardiology, National and Kapodistrian University of Athens, Medical School, Sotiria Chest Disease Hospital , 152 Mesogeion St, Athens 11527 , Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0754-1964","authenticated-orcid":false,"given":"Efstratios","family":"Katsianos","sequence":"additional","affiliation":[{"name":"3rd Department of Cardiology, National and Kapodistrian University of Athens, Medical School, Sotiria Chest Disease Hospital , 152 Mesogeion St, Athens 11527 , Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9260-6306","authenticated-orcid":false,"given":"Panagiotis","family":"Theofilis","sequence":"additional","affiliation":[{"name":"3rd Department of Cardiology, National and Kapodistrian University of Athens, Medical School, Sotiria Chest Disease Hospital , 152 Mesogeion St, Athens 11527 , Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerasimos","family":"Siasos","sequence":"additional","affiliation":[{"name":"3rd Department of Cardiology, National and Kapodistrian University of Athens, Medical School, Sotiria Chest Disease Hospital , 152 Mesogeion St, Athens 11527 , Greece"},{"name":"Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School , 75 Francis St, Boston, MA 02115 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael Andrew","family":"Vavuranakis","sequence":"additional","affiliation":[{"name":"3rd Department of Cardiology, National and Kapodistrian University of Athens, Medical School, Sotiria Chest Disease Hospital , 152 Mesogeion St, Athens 11527 , Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexios S","family":"Antonopoulos","sequence":"additional","affiliation":[{"name":"Clinical, Experimental Surgery & Translational Research Center, Biomedical Research Foundation of the Academy of Athens , 4 Soranou Ephessiou St, Athens 11527 , Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7492-4984","authenticated-orcid":false,"given":"Dimitris","family":"Tousoulis","sequence":"additional","affiliation":[{"name":"1st Department of Cardiology, National and Kapodistrian University of Athens, Medical School, Ippokrateio Hospital , 114 Vasilissis Sofias St, Athina 11527 , Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manolis","family":"Vavouranakis","sequence":"additional","affiliation":[{"name":"3rd Department of Cardiology, National and Kapodistrian University of Athens, Medical School, Sotiria Chest Disease Hospital , 152 Mesogeion St, Athens 11527 , Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,4,20]]},"reference":[{"key":"2023120716442223500_cvad062-B1","doi-asserted-by":"crossref","first-page":"16006","DOI":"10.1038\/nrdp.2016.6","article-title":"Calcific aortic stenosis","volume":"2","author":"Lindman","year":"2016","journal-title":"Nat Rev Dis Primer"},{"key":"2023120716442223500_cvad062-B2","first-page":"269","volume-title":"Cardiology secrets","author":"Levine","year":"2018","edition":"5th ed"},{"key":"2023120716442223500_cvad062-B3","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1093\/cvr\/cvab060","article-title":"Apolipoprotein B is an insufficient explanation for the risk of coronary disease associated with lipoprotein(a)","volume":"117","author":"Trinder","year":"2021","journal-title":"Cardiovasc Res"},{"key":"2023120716442223500_cvad062-B4","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1136\/heartjnl-2021-320173","article-title":"Lipoprotein(a) and aortic stenosis","volume":"108","author":"Chan","year":"2022","journal-title":"Heart"},{"key":"2023120716442223500_cvad062-B5","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.jacc.2016.11.042","article-title":"A test in context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies","volume":"69","author":"Tsimikas","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2023120716442223500_cvad062-B6","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s10557-016-6648-3","article-title":"Human genetics and the causal role of lipoprotein(a) for various diseases","volume":"30","author":"Kronenberg","year":"2016","journal-title":"Cardiovasc Drugs Ther"},{"key":"2023120716442223500_cvad062-B7","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1177\/0003319716688415","article-title":"The prevalence of lipoprotein(a) measurement and degree of elevation among 2710 patients with calcific aortic valve stenosis in an academic echocardiography laboratory setting","volume":"68","author":"Wilkinson","year":"2017","journal-title":"Angiology"},{"key":"2023120716442223500_cvad062-B8","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1093\/eurheartj\/ehac361","article-title":"Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European atherosclerosis society consensus statement","volume":"43","author":"Kronenberg","year":"2022","journal-title":"Eur Heart J"},{"key":"2023120716442223500_cvad062-B9","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1161\/CIRCGENETICS.113.000400","article-title":"Lipoprotein(a) levels, genotype, and incident aortic valve stenosis: a prospective Mendelian randomization study and replication in a case-control cohort","volume":"7","author":"Arsenault","year":"2014","journal-title":"Circ Cardiovasc Genet"},{"key":"2023120716442223500_cvad062-B10","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.atherosclerosis.2022.06.003","article-title":"Sex-and race-specific burden of aortic valve calcification among older adults without overt coronary heart disease: the atherosclerosis risk in communities study","volume":"355","author":"Boakye","year":"2022","journal-title":"Atherosclerosis"},{"key":"2023120716442223500_cvad062-B11","first-page":"1826","article-title":"Association of inflammatory, lipid and mineral markers with cardiac calcification in older adults","volume":"102","author":"Bortnick","year":"2016","journal-title":"Heart Br Card Soc"},{"key":"2023120716442223500_cvad062-B12","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.jacbts.2020.06.012","article-title":"Interaction of autotaxin with lipoprotein(a) in patients with calcific aortic valve stenosis","volume":"5","author":"Bourgeois","year":"2020","journal-title":"JACC Basic Transl Sci"},{"key":"2023120716442223500_cvad062-B13","first-page":"387","article-title":"Effects of serum levels of novel atherosclerotic risk factors on aortic valve calcification","volume":"16","author":"Bozbas","year":"2007","journal-title":"J Heart Valve Dis"},{"key":"2023120716442223500_cvad062-B14","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1373\/clinchem.2016.270751","article-title":"Evaluation of lipoprotein(a) electrophoretic and immunoassay methods in discriminating risk of calcific aortic valve disease and incident coronary heart disease: the multi-ethnic study of atherosclerosis","volume":"63","author":"Cao","year":"2017","journal-title":"Clin Chem"},{"key":"2023120716442223500_cvad062-B15","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1016\/j.jacc.2015.07.020","article-title":"Oxidized phospholipids, lipoprotein(a), and progression of calcific aortic valve stenosis","volume":"66","author":"Capoulade","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"2023120716442223500_cvad062-B16","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1001\/jamacardio.2018.3798","article-title":"Association of mild to moderate aortic valve stenosis progression with higher lipoprotein(a) and oxidized phospholipid levels: secondary analysis of a randomized clinical trial","volume":"3","author":"Capoulade","year":"2018","journal-title":"JAMA Cardiol"},{"key":"2023120716442223500_cvad062-B17","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1136\/heartjnl-2019-315840","article-title":"ApoCIII-Lp(a) complexes in conjunction with lp(a)-OxPL predict rapid progression of aortic stenosis","volume":"106","author":"Capoulade","year":"2020","journal-title":"Heart"},{"key":"2023120716442223500_cvad062-B18","doi-asserted-by":"publisher","DOI":"10.1136\/pmj-2022-141721","article-title":"Epidemiological study of calcified aortic valve stenosis in a Chinese community population","author":"Chen","year":"2022","journal-title":"Postgrad Med J"},{"key":"2023120716442223500_cvad062-B19","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.cjco.2019.03.004","article-title":"Lipoprotein(a), oxidized phospholipids, and aortic valve microcalcification assessed by 18F-sodium fluoride positron emission tomography and computed tomography","volume":"1","author":"Despr\u00e9s","year":"2019","journal-title":"CJC Open"},{"key":"2023120716442223500_cvad062-B20","doi-asserted-by":"crossref","DOI":"10.1177\/0300060520965353","article-title":"Correlations between lipoprotein(a) gene polymorphisms and calcific aortic valve disease and coronary heart disease in Han Chinese","volume":"48","author":"Dong","year":"2020","journal-title":"J Int Med Res"},{"key":"2023120716442223500_cvad062-B21","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/S0195-668X(02)00385-8","article-title":"Lipoprotein(a), chlamydia pneumoniae, leptin and tissue plasminogen activator as risk markers for valvular aortic stenosis","volume":"24","author":"Glader","year":"2003","journal-title":"Eur Heart J"},{"key":"2023120716442223500_cvad062-B22","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/S0002-9149(99)80263-X","article-title":"Correlation between lipoprotein(a) and aortic valve sclerosis assessed by echocardiography (the JMS cardiac echo and cohort study)","volume":"76","author":"Gotoh","year":"1995","journal-title":"Am J Cardiol"},{"key":"2023120716442223500_cvad062-B23","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1016\/j.jacc.2019.10.019","article-title":"Lipoprotein(a) concentration and risks of cardiovascular disease and diabetes","volume":"74","author":"Gudbjartsson","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2023120716442223500_cvad062-B24","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1093\/ehjci\/jev338","article-title":"Lipoprotein(a) is a risk factor for aortic and mitral valvular stenosis in peripheral arterial disease","volume":"17","author":"Hojo","year":"2016","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2023120716442223500_cvad062-B25","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.jacl.2020.12.006","article-title":"Subjects with familial hypercholesterolemia have lower aortic valve area and higher levels of inflammatory biomarkers","volume":"15","author":"Hovland","year":"2021","journal-title":"J Clin Lipidol"},{"key":"2023120716442223500_cvad062-B26","first-page":"61","article-title":"Lipoprotein(a) has no major impact on calcification activity in patients with mild to moderate aortic valve stenosis","volume":"108","author":"Kaiser","year":"2022","journal-title":"Heart Br Card Soc"},{"key":"2023120716442223500_cvad062-B27","first-page":"1422","article-title":"Lipoprotein(a) is robustly associated with aortic valve calcium","volume":"107","author":"Kaiser","year":"2021","journal-title":"Heart Br Card Soc"},{"key":"2023120716442223500_cvad062-B28","doi-asserted-by":"crossref","first-page":"3960","DOI":"10.1093\/eurheartj\/ehac377","article-title":"Lipoprotein(a) is associated with the onset but not the progression of aortic valve calcification","volume":"43","author":"Kaiser","year":"2022","journal-title":"Eur Heart J"},{"key":"2023120716442223500_cvad062-B29","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.atherosclerosis.2021.11.029","article-title":"Elevated lipoprotein(a) in mitral and aortic valve calcification and disease: the Copenhagen general population study","volume":"349","author":"Kaltoft","year":"2022","journal-title":"Atherosclerosis"},{"key":"2023120716442223500_cvad062-B30","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.jacc.2021.11.043","article-title":"Lipoprotein(a) and body mass compound the risk of calcific aortic valve disease","volume":"79","author":"Kaltoft","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2023120716442223500_cvad062-B31","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.jacc.2013.09.038","article-title":"Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population","volume":"63","author":"Kamstrup","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"2023120716442223500_cvad062-B32","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1161\/ATVBAHA.116.308761","article-title":"Oxidized phospholipids and risk of calcific aortic valve disease: the Copenhagen general population study","volume":"37","author":"Kamstrup","year":"2017","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2023120716442223500_cvad062-B33","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1210\/jc.2015-1096","article-title":"Elevated lipoprotein(a) does not cause low-grade inflammation despite causal association with aortic valve stenosis and myocardial infarction: a study of 100,578 individuals from the general population","volume":"100","author":"Langsted","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"2023120716442223500_cvad062-B34","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.2337\/dc19-1398","article-title":"The association of lipoprotein(a) plasma levels with prevalence of cardiovascular disease and metabolic control status in patients with type 1 diabetes","volume":"43","author":"Littmann","year":"2020","journal-title":"Diabetes Care"},{"key":"2023120716442223500_cvad062-B35","first-page":"133","article-title":"Association of serum lipoprotein(a) level with the severity and prognosis of calcific aortic valve stenosis: a Chinese cohort study","volume":"17","author":"Liu","year":"2020","journal-title":"J Geriatr Cardiol JGC"},{"key":"2023120716442223500_cvad062-B36","doi-asserted-by":"crossref","first-page":"e007160","DOI":"10.1161\/JAHA.117.007160","article-title":"Lipoprotein(a) and the apolipoprotein B\/A1 ratio independently associate with surgery for aortic stenosis only in patients with concomitant coronary artery disease","volume":"6","author":"Ljungberg","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"2023120716442223500_cvad062-B37","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.amjcard.2018.04.046","article-title":"Comparison of lipoprotein(a)-levels in patients \u226570 years of age with versus without aortic valve stenosis","volume":"122","author":"Mahabadi","year":"2018","journal-title":"Am J Cardiol"},{"key":"2023120716442223500_cvad062-B38","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.atherosclerosis.2020.09.010","article-title":"Lipoprotein (a) and aortic valve calcium in South Asians compared to other race\/ethnic groups","volume":"313","author":"Makshood","year":"2020","journal-title":"Atherosclerosis"},{"key":"2023120716442223500_cvad062-B39","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/joim.12519","article-title":"Autotaxin interacts with lipoprotein(a) and oxidized phospholipids in predicting the risk of calcific aortic valve stenosis in patients with coronary artery disease","volume":"280","author":"Nsaibia","year":"2016","journal-title":"J Intern Med"},{"key":"2023120716442223500_cvad062-B40","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.024870","article-title":"Lipoprotein(a) and subclinical vascular and valvular calcification on cardiac computed tomography: the atherosclerosis risk in communities study","volume":"11","author":"Obisesan","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"2023120716442223500_cvad062-B41","first-page":"31","article-title":"Lipoprotein(a) gene polymorphism increases a risk factor for aortic valve calcification","volume":"6","author":"Ozkan","year":"2019","journal-title":"J Cardiovasc Dev Dis"},{"key":"2023120716442223500_cvad062-B42","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.atherosclerosis.2022.06.1023","article-title":"Sex differences of lipoprotein(a) levels and associated risk of morbidity and mortality by age: the Copenhagen general population study","volume":"355","author":"Simony","year":"2022","journal-title":"Atherosclerosis"},{"key":"2023120716442223500_cvad062-B43","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/S0735-1097(96)00563-3","article-title":"Clinical factors associated with calcific aortic valve disease. Cardiovascular health study","volume":"29","author":"Stewart","year":"1997","journal-title":"J Am Coll Cardiol"},{"key":"2023120716442223500_cvad062-B44","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s11739-018-1925-8","article-title":"Role of lipoprotein (a) and LPA KIV2 repeat polymorphism in bicuspid aortic valve stenosis and calcification: a proof of concept study","volume":"14","author":"Sticchi","year":"2019","journal-title":"Intern Emerg Med"},{"key":"2023120716442223500_cvad062-B45","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0181077","article-title":"Lipoprotein(a) in patients with aortic stenosis: insights from cardiovascular magnetic resonance","volume":"12","author":"Vassiliou","year":"2017","journal-title":"PLoS One"},{"key":"2023120716442223500_cvad062-B46","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/joim.12335","article-title":"Lipoprotein(a) levels are associated with aortic valve calcification in asymptomatic patients with familial hypercholesterolaemia","volume":"278","author":"Vongpromek","year":"2015","journal-title":"J Intern Med"},{"key":"2023120716442223500_cvad062-B47","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1177\/0300060516648030","article-title":"Proprotein convertase subtilisin\/kexin type 9 levels and aortic valve calcification: a prospective, cross sectional study","volume":"44","author":"Wang","year":"2016","journal-title":"J Int Med Res"},{"key":"2023120716442223500_cvad062-B48","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1080\/00015385.2022.2129183","article-title":"The nonlinear correlation between lipoprotein (a) and the prevalence of aortic valve calcification in patients with new-onset acute myocardial infarction","volume":"77","author":"Wang","year":"2022","journal-title":"Acta Cardiol"},{"key":"2023120716442223500_cvad062-B49","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.atherosclerosis.2022.02.016","article-title":"Plasma lipoprotein(a) measured in routine clinical care and the association with incident calcified aortic valve stenosis during a 14-year observational period","volume":"349","author":"Wodaje","year":"2022","journal-title":"Atherosclerosis"},{"key":"2023120716442223500_cvad062-B50","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.013020","article-title":"Apob\/apoA-I ratio and lp(a) associations with aortic valve stenosis incidence: insights from the EPIC-norfolk prospective population study","volume":"8","author":"Zheng","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"2023120716442223500_cvad062-B51","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1016\/j.jacc.2019.01.070","article-title":"Lipoprotein(a) and oxidized phospholipids promote valve calcification in patients with aortic stenosis","volume":"73","author":"Zheng","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2023120716442223500_cvad062-B52","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.ijcard.2018.11.094","article-title":"Effects of the coronary artery disease associated LPA and 9p21 loci on risk of aortic valve stenosis","volume":"276","author":"Trenkwalder","year":"2019","journal-title":"Int J Cardiol"},{"key":"2023120716442223500_cvad062-B53","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1001\/jamacardio.2019.1581","article-title":"Genetic variation in LPA, calcific aortic valve stenosis in patients undergoing cardiac surgery, and familial risk of aortic valve microcalcification","volume":"4","author":"Perrot","year":"2019","journal-title":"JAMA Cardiol"},{"key":"2023120716442223500_cvad062-B54","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1161\/CIRCULATIONAHA.116.026103","article-title":"Genome-wide significant association of aortic stenosis with a genetic variant for lipoprotein(a): meta-analysis of published and novel data","volume":"135","author":"Cairns","year":"2017","journal-title":"Circulation"},{"key":"2023120716442223500_cvad062-B55","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1038\/s41467-018-03252-6","article-title":"Genome-wide analysis yields new loci associating with aortic valve stenosis","volume":"9","author":"Helgadottir","year":"2018","journal-title":"Nat Commun"},{"key":"2023120716442223500_cvad062-B56","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.989539","article-title":"IL6 Gene polymorphism association with calcific aortic valve stenosis and influence on serum levels of interleukin-6","volume":"9","author":"Junco-Vicente","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"2023120716442223500_cvad062-B57","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1001\/jamacardio.2017.4266","article-title":"Association of LPA variants with aortic stenosis: a large-scale study using diagnostic and procedural codes from electronic health records","volume":"3","author":"Chen","year":"2018","journal-title":"JAMA Cardiol"},{"key":"2023120716442223500_cvad062-B58","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa1109034","article-title":"Genetic associations with valvular calcification and aortic stenosis","volume":"368","author":"Thanassoulis","year":"2013","journal-title":"N Engl J Med"},{"key":"2023120716442223500_cvad062-B59","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1590\/1678-4685-gmb-2017-0371","article-title":"The rs10455872-G allele of the LPA gene is associated with high lipoprotein(a) levels and increased aortic valve calcium in a Mexican adult population","volume":"42","author":"Cardoso-Salda\u00f1a","year":"2019","journal-title":"Genet Mol Biol"},{"key":"2023120716442223500_cvad062-B60","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1016\/j.jacc.2016.10.033","article-title":"Phenotypic characterization of genetically lowered human lipoprotein(a) levels","volume":"68","author":"Emdin","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2023120716442223500_cvad062-B61","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1093\/eurheartj\/ehab395","article-title":"2021 ESC\/EACTS guidelines for the management of valvular heart disease","volume":"43","author":"Vahanian","year":"2022","journal-title":"Eur Heart J"},{"key":"2023120716442223500_cvad062-B62","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2022.812368","article-title":"Lipoprotein(a), a lethal player in calcific aortic valve disease","volume":"10","author":"Hu","year":"2022","journal-title":"Front Cell Dev Biol"},{"key":"2023120716442223500_cvad062-B63","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.pcad.2020.06.002","article-title":"Lipoprotein(a) and calcific aortic valve stenosis: a systematic review","volume":"63","author":"Guddeti","year":"2020","journal-title":"Prog Cardiovasc Dis"},{"key":"2023120716442223500_cvad062-B64","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1097\/HCO.0000000000000901","article-title":"The current landscape of lipoprotein(a) in calcific aortic valvular disease","volume":"36","author":"Hsieh","year":"2021","journal-title":"Curr Opin Cardiol"},{"key":"2023120716442223500_cvad062-B65","doi-asserted-by":"crossref","first-page":"6040","DOI":"10.3390\/jcm11206040","article-title":"Lipoprotein(a): evidence for role as a causal risk factor in cardiovascular disease and emerging therapies","volume":"11","author":"Bhatia","year":"2022","journal-title":"J Clin Med"},{"key":"2023120716442223500_cvad062-B66","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.numecd.2021.10.015","article-title":"Lipoprotein(a) and aortic valve stenosis: a casual or causal association?","volume":"32","author":"Santangelo","year":"2022","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"2023120716442223500_cvad062-B67","article-title":"Association between lipoprotein(a) and calcific aortic valve disease: a systematic review and meta-analysis","volume":"9","author":"Liu","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"2023120716442223500_cvad062-B68","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.ahj.2004.10.036","article-title":"The prevalence of bicuspid aortic valve in newborns by echocardiographic screening","volume":"150","author":"Tutar","year":"2005","journal-title":"Am Heart J"},{"key":"2023120716442223500_cvad062-B69","doi-asserted-by":"crossref","first-page":"5620","DOI":"10.3390\/ijms21165620","article-title":"Sex-specific features of calcific aortic valve disease","volume":"21","author":"Summerhill","year":"2020","journal-title":"Int J Mol Sci"},{"key":"2023120716442223500_cvad062-B70","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1161\/CIRCRESAHA.116.309306","article-title":"Sex-related discordance between aortic valve calcification and hemodynamic severity of aortic stenosis: is valvular fibrosis the explanation?","volume":"120","author":"Simard","year":"2017","journal-title":"Circ Res"},{"key":"2023120716442223500_cvad062-B71","doi-asserted-by":"crossref","first-page":"685","DOI":"10.3389\/fphar.2020.00685","article-title":"Calcific aortic valve disease-natural history and future therapeutic strategies","volume":"11","author":"Alushi","year":"2020","journal-title":"Front Pharmacol"},{"key":"2023120716442223500_cvad062-B72","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1210\/en.2008-0760","article-title":"Androgen-induced progression of arterial calcification in apolipoprotein E-null mice is uncoupled from plaque growth and lipid levels","volume":"150","author":"McRobb","year":"2009","journal-title":"Endocrinology"},{"key":"2023120716442223500_cvad062-B73","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1210\/jc.2003-030334","article-title":"Prevalence and predictors of coronary artery calcification in women with polycystic ovary syndrome","volume":"88","author":"Christian","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"2023120716442223500_cvad062-B74","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.jacc.2017.11.014","article-title":"NHLBI Working group recommendations to reduce lipoprotein(a)-mediated risk of cardiovascular disease and aortic stenosis","volume":"71","author":"Tsimikas","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2023120716442223500_cvad062-B75","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/j.jacl.2018.07.003","article-title":"Relationship of lipoprotein(a) molar concentrations and mass according to lipoprotein(a) thresholds and apolipoprotein(a) isoform size","volume":"12","author":"Tsimikas","year":"2018","journal-title":"J Clin Lipidol"},{"key":"2023120716442223500_cvad062-B76","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1161\/CIRCULATIONAHA.116.024611","article-title":"LPA Gene, ethnicity, and cardiovascular events","volume":"135","author":"Lee","year":"2017","journal-title":"Circulation"},{"key":"2023120716442223500_cvad062-B77","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","article-title":"Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy","volume":"365","author":"AIM-HIGH Investigators","year":"2011","journal-title":"N Engl J Med"},{"key":"2023120716442223500_cvad062-B78","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1161\/CIRCULATIONAHA.118.037184","article-title":"Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk: insights from the FOURIER trial","volume":"139","author":"O\u2019Donoghue","year":"2019","journal-title":"Circulation"},{"key":"2023120716442223500_cvad062-B79","doi-asserted-by":"crossref","first-page":"4245","DOI":"10.1093\/eurheartj\/ehaa649","article-title":"Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial","volume":"41","author":"Szarek","year":"2020","journal-title":"Eur Heart J"},{"key":"2023120716442223500_cvad062-B80","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1093\/cvr\/cvab247","article-title":"The size of apolipoprotein (a) is an independent determinant of the reduction in lipoprotein (a) induced by PCSK9 inhibitors","volume":"118","author":"Blanchard","year":"2022","journal-title":"Cardiovasc Res"},{"key":"2023120716442223500_cvad062-B81","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1056\/NEJMoa1009744","article-title":"Safety of anacetrapib in patients with or at high risk for coronary heart disease","volume":"363","author":"Cannon","year":"2010","journal-title":"N Engl J Med"},{"key":"2023120716442223500_cvad062-B82","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1001\/jama.2011.1649","article-title":"Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial","volume":"306","author":"Nicholls","year":"2011","journal-title":"JAMA"},{"key":"2023120716442223500_cvad062-B83","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1056\/NEJMoa1905239","article-title":"Lipoprotein(a) reduction in persons with cardiovascular disease","volume":"382","author":"Tsimikas","year":"2020","journal-title":"N Engl J Med"},{"key":"2023120716442223500_cvad062-B84","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/j.clinthera.2022.07.008","article-title":"Pharmacokinetics, pharmacodynamics, and tolerability of olpasiran in healthy Japanese and non-Japanese participants: results from a phase I, single-dose, open-label study","volume":"44","author":"Sohn","year":"2022","journal-title":"Clin Ther"},{"key":"2023120716442223500_cvad062-B85","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/s41591-021-01634-w","article-title":"Preclinical development and phase 1 trial of a novel siRNA targeting lipoprotein(a)","volume":"28","author":"Koren","year":"2022","journal-title":"Nat Med"},{"key":"2023120716442223500_cvad062-B86","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1001\/jama.2022.5050","article-title":"Single ascending dose study of a short interfering RNA targeting lipoprotein(a) production in individuals with elevated plasma lipoprotein(a) levels","volume":"327","author":"Nissen","year":"2022","journal-title":"JAMA"}],"container-title":["Cardiovascular Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cardiovascres\/advance-article-pdf\/doi\/10.1093\/cvr\/cvad062\/50264616\/cvad062.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cardiovascres\/article-pdf\/119\/8\/1641\/54083251\/cvad062.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cardiovascres\/article-pdf\/119\/8\/1641\/54083251\/cvad062.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T17:38:10Z","timestamp":1701970690000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cardiovascres\/article\/119\/8\/1641\/7133182"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,20]]},"references-count":86,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023,4,20]]},"published-print":{"date-parts":[[2023,7,6]]}},"URL":"https:\/\/doi.org\/10.1093\/cvr\/cvad062","relation":{},"ISSN":["0008-6363","1755-3245"],"issn-type":[{"value":"0008-6363","type":"print"},{"value":"1755-3245","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,6]]},"published":{"date-parts":[[2023,4,20]]}}}